CAR-T product development: an assessment of FDA’s final guidance for industry

5 min

By Steve Winitsky, M.D., Senior Vice President, Technical, Regulatory Consulting

Christiane Niederlaender, Ph.D., Vice President, Technical, Regulatory Consulting

Rajiv Gangurde, Ph.D., Vice President Technical - Regulatory Consulting

Published on: Feb 27, 2024

The FDA released its final industry guidance for CAR-T developers on January 29, following a draft published in March 2022. Experts from Parexel Regulatory Strategy, including ex-FDA and EMA regulators, share their insight into the guidance’s clinical, non-clinical and CMC recommendations.  

CAR T-cells are gene therapy products regulated under FDA’s existing framework for biological products. The agency recognizes the specific complexity and challenge of development in this space, with this document offering recommendations to further guide sponsors. It focuses on oncology indications, including hematologic malignancies and solid tumors without explicitly addressing other treatment areas, such as autoimmune diseases. Considerations for “non-traditional” indications are still being studied and may possess significantly different benefit-risk considerations due to concerns of secondary T-cell malignancy. 

Notably, the guidance does not specifically mention the recent FDA investigation into secondary T-cell malignancies in patients treated with approved CAR-T products. This absence indicates that the FDA is still interpreting and assessing the findings. Nonetheless, the content of the guidance does not imply a significant change in the FDA's benefit-risk assessment for CAR-Ts. For instance, the recommended long-term follow-up (LTFU) duration of 15 years for patients who have received CAR-Ts manufactured using integrating vectors remains unchanged in the final guidance, compared to the draft guidance that preceded the recent T-cell malignancy issue. 

Overall, this guidance balances class-wide regulatory considerations for CAR-Ts, while emphasizing the importance of individualized FDA review of benefit-risk, based on the unique characteristics of each investigational CAR-T product/indication.

Return to Insights Center

Related Insights

Blog

Making cell and gene therapy more accessible in the treatment of solid tumors

Jun 4, 2024

Podcast

Rare endpoints: Delivering on unmet patient needs

May 7, 2024

Podcast

CAR-T boxed warnings: What comes next?

Mar 6, 2024

Blog

CAR-T boxed warnings: regulatory precedents and opportunities

Feb 9, 2024

Report

New Medicines, Novel Insights: Accelerating development of cell and gene therapies

May 22, 2023

Playbook

Mitigating risk, protecting potential: Practical strategies that position cell and gene therapy development for success

Mar 28, 2023

Video

Cell & Gene Therapies: A Regulatory Update

Jul 22, 2022

Blog

Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial

Nov 19, 2021

Article

Three ways to improve your chances that insurers will pay for a new CGT

Feb 18, 2021

Blog

Cell & Gene Unscripted: Real-world evidence

Sep 16, 2026

Blog

Cell & Gene Unscripted: Rare and genetic diseases

Sep 16, 2026

Blog

Cell & Gene Unscripted: Rethinking clinical research

Sep 16, 2026

Related Insights

Blog

Making cell and gene therapy more accessible in the treatment of solid tumors

Jun 4, 2024

Podcast

Rare endpoints: Delivering on unmet patient needs

May 7, 2024

Podcast

CAR-T boxed warnings: What comes next?

Mar 6, 2024

Blog

CAR-T boxed warnings: regulatory precedents and opportunities

Feb 9, 2024

Report

New Medicines, Novel Insights: Accelerating development of cell and gene therapies

May 22, 2023

Playbook

Mitigating risk, protecting potential: Practical strategies that position cell and gene therapy development for success

Mar 28, 2023

Video

Cell & Gene Therapies: A Regulatory Update

Jul 22, 2022

Blog

Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial

Nov 19, 2021

Article

Three ways to improve your chances that insurers will pay for a new CGT

Feb 18, 2021

Blog

Cell & Gene Unscripted: Real-world evidence

Sep 16, 2026

Blog

Cell & Gene Unscripted: Rare and genetic diseases

Sep 16, 2026

Blog

Cell & Gene Unscripted: Rethinking clinical research

Sep 16, 2026

Show more

Back

Access exclusive insights

Harness the power of clinical development with exclusive insights from our experts at Parexel

Would you like to hear from us in the future?

Stay connected with Parexel!

Accept

Decline